Search Results - "Pathil, A"

P0442 : UDCA-LPE modulates different signaling pathways involved in hepatic fibrogenesis by Su, J, Chamulitrat, W, Stremmel, W, Pathil, A

Get full text

The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl Lysophosphatidylethanolamide Disturbs Pro-Fibrogenic Integrin and TGFB Signaling by Su, J, Gan-Schreier, H, Chamulitrat, W, Stremmel, W, Pathil, A

Get full text

Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R) by Vermehren, J, Athmann, C, Günther, R, Schott, E, Pathil, A, Boeker, K.H, Cornberg, M, Niederau, C, Simon, K.-G, Maasoumy, B, Sarrazin, C, Wedemeyer, H, Buggisch, P, C-Registry, G.H

Get full text

Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R) by Deterding, K, Mauss, S, Pathil, A, Buggisch, P, Schott, E, Cornberg, M, Zimmermann, T, Simon, K.-G, Klinker, H, Günther, R, Pfeiffer-Vornkahl, H, Hueppe, D, Sarrazin, C, Zeuzem, S, Manns, M.P, Wedemeyer, H, Berg, T

Get full text

Ledipasvir/Sofosbuvir Treatment for 8 Weeks in Treatment-Naïve HCV Genotype 1 Infected Patients under Real Life Conditions: Data from the German Hepatitis C-Registry (DHC-R) by Buggisch, P, Böker, K.H.W, Günther, R, Teuber, G, Klinker, H, Pathil, A, Christensen, S, Peiffer-Vornkahl, H, Simon, K.-G, Niederau, C, Wedemeyer, H, Zeuzem, S

Get full text

Carriers of the ABCB4 PT175A Allele might be At-Risk of Increased Liver Injury: Analysis of Two Independent Cohorts of Patients by Krawczyk, M, Rau, M, Schattenberg, J, Grünhage, F, Bantel, H, Pathil, A, Demir, M, Kluwe, J, Boettler, T, Geier, A, Lammert, F

Get full text

Point-of-care PT and aPTT in patients with suspected deficiencies of coagulation factors by Niederdöckl, J., Dempfle, C.-E., Schönherr, H.-R., Bartsch, A., Miles, G., Laggner, A., Pathil, A.

“…Summary Introduction There are several clinical settings and patient conditions especially in intensive care units, emergency departments, and operating…”
Get full text

Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The Hepnet Acute HCV IV Study by Deterding, K, Spinner, C, Schott, E, Welzel, T, Gerken, G, Klinker, H, Spengler, U, Wiegand, J, Schulze zur Wiesch, J, Pathil, A, Cornberg, M, Umgelter, A, Zöllner, C, Zeuzem, S, von der Leyen, H, von Witzendorff, D, Manns, M.P, Wedemeyer, H

Get full text

1281 URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE (UDCA-LPE) EVOKES HEPATOPROTECTION VIA G-PROTEIN COUPLED RECEPTORS AND BY MODULATING DESATURASE GENE EXPRESSION by Chamulitrat, W, Xu, W, Katava, N, Pathil, A, Stremmel, W

Get full text

117 THE BILE ACID PHOSPHOLIPID CONJUGATE URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE EXERTS ANTI-FIBROGENIC EFFECTS AND INHIBITS EPITHELIAL-TO-MESENCHYMAL TRANSITION BY BLOCKING TGFβ1/SMAD2/3 SIGNALING by Pathil, A, Müller, J, Warth, A, Chamulitrat, W, Stremmel, W

Get full text

132 IMPROVEMENT OF HEPATIC INJURY AND STEATOSIS BY THE BILE ACID-PHOSPHOLIPID CONJUGATE UR- SODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE IN A HIGH-FAT INDUCED DIETARY MODEL OF NONALCOHOLIC FATTY LIVER DISEASE by Pathil, A, Warth, A, Chamulitrat, W, Stremmel, W

Get full text

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study by Lampertico, Pietro, Berg, Thomas, Buti, Maria, Pathil, Anita, Petersen, Joerg, Ryder, Stephen D., Zoulim, Fabien, Botros, Irina, Flaherty, John F., Jump, Belinda, Op den Brouw, Marjoleine L., Troostenburg, Anna, Ramroth, Heribert, Bourlière, M., De Ledinghen, V., Riachi, G., Zoulim, F., Loustaud‐Ratti, V., Tran, A., Larrey, D., Dumortier, J., Leroy, V., Metivier, S., Sellier, P., Mauss, S., Peterson, J., Berg, T., Schiefke, I., Niederau, C., Teuber, G., Goeser, T., Jung, M. C., Grambihler, A., Pathil‐Warth, A., Sprinzl, K., Von der Ohe, M., Antoni, C., Weigand, K., Andreone, P., Lampertico, P., Di Marco, V., Madonia, S., Puoti, M., Santantonio, T., Vigano, M., Ciancio, A., D'Offizi, G., Pirisi, M., Buti, M., Suarez Garcia, E., Pascasio Acevedo, J. M, Andrade, R., Gea, F., Serra Desfilis, M. A., Molina Perez, E., Manzano Alonso, M., Carrion, J. A., Aoufi Rabih, S., Planas, M. M., Ryder, S., Agarwal, K., Ustianowski, A., Aspinall, R., Kennedy, P., Geretti, A. M., McCorry, R., Foxton, M., Healy, B.

“…Summary Background Limited data exist regarding tenofovir disoproxil fumarate (TDF) safety and effectiveness in chronic hepatitis B virus–infected (CHB)…”
Get full text

P0934 : Lysophosphatidylcholine (LPC) as central player for hepatic fat accumulation and inflammation: Implication for pathogenesis of NASH by Stremmel, W, Staffer, S, Wannhoff, A, Pathil-Warth, A, Chamulitrat, W

Get full text

High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis by Schwarz, J, Werner, C, Steurer, M, Spengler, U, Wedemeyer, H, von Hahn, T, Stremmel, W, Pathil-Warth, A, Berg, T, Engelmann, C, Seybold, U, Schott, E, Blessin, U, Malek, N, Lauer, U, Berg, C

Get full text

Add on Interferon-Alpha-2a for the Treatment of HBeAg Negative Hepatitis B Patients Receiving Effective Nucleos(t)ide Therapy: Interim Results of the Prospective Multicentre PADD-On Trial by Sprinzl, M.F, Grambihler, A, Teuber, G, Ebert, M, Zeuzem, S, Lohmeyer, J, Cornberg, M, Tacke, F, Löhr, H, Berg, T, Lammert, F, Schott, E, Heyne, R, Berg, C, Dollinger, M, Pathil-Warth, A, Geisler, F, Spengler, U, Thimme, R, Weigand, K, Alshuth, U, Ehrlich, A, Riedl, M, Kittner, J, Schuchmann, M, Galle, P.R

Get full text

20 DEFICIENCIES OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 BETA IN VIVO CAUSES REDUCED SYSTEMIC LIPIDS AND LIPOPROTEINS CONCOMITANT WITH INCREASED HEPATIC APOPTOSIS AND INFLAMMATION by Xu, W, Tuma, S, Katava, N, Pathil-Warth, A, Stremmel, W, Chamulitrat, W

Get full text

First data concerning the medical supply of patients with non-alcoholic fatty liver disease in Germany - a survey in university hospital centers of hepatology by Weiss, J, Rau, M, Bantel, H, Bock, H, Demir, M, Kluwe, J, Krawczyk, M, Pathil-Warth, A, Schattenberg, J M, Tacke, F, Roeb, E, Geier, A

“…Non-alcoholic fatty liver disease (NAFLD) currently is one oft the most common reasons for chronic liver injury in the western world. In the European and…”
Get more information

1221 URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE GENERATES HEPATOPROTECTIVE CONJUGATED UDCA, PHOSPHATIDYLCHOLINE, MEDIUM-CHAIN FATTY ACIDS AND PLASMALOGEN 16:1 by Chamulitrat, W, Xu, W, Pathil-Warth, A, Liebisch, G, Schmitz, G, Zhang, W, Setchell, K, Stremmel, W

Get full text

SAT-407 - The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl Lysophosphatidylethanolamide Disturbs Pro-Fibrogenic Integrin and TGFB Signaling by Su, J., Gan-Schreier, H., Chamulitrat, W., Stremmel, W., Pathil, A.

Get full text

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate by ARMEANU, Sorin, BITZER, Michael, STEINLE, Alexander, SALIH, Helmut R, LAUER, Ulrich M, VENTURELLI, Sascha, PATHIL, Anita, KRUSCH, Matthias, KAISER, Stephan, JOBST, Jurgen, SMIRNOW, Irina, WAGNER, Annika

“…Natural killer (NK) cells as components of the innate immunity substantially contribute to antitumor immune responses. However, the tumor-associated ligands…”
Get full text